The company has successfully developed and mass-produced ONX-1006, a non-toxic, highly effective nanomedicine. This innovative nano-delivery technology precisely targets and induces apoptosis in tumor cells, effectively eliminating treatment-related adverse events while delivering exceptional efficacy. As a result, ONX-1006 is expected to significantly reduce the pancreatic cancer death rate and achieve a 70% 5-year survival rate, with minimal to no side effects.